Tirzepatide vs. Semaglutide vs. Retatrutide: Which Are the Best Peptides for Weight Loss?
Key Takeaways
- Semaglutide is a single-action GLP-1 receptor agonist that slows digestion and signals fullness to the brain.
- Tirzepatide is a dual-action GIP and GLP-1 receptor agonist, targeting two different hormones that help regulate appetite and metabolism.
- Retatrutide is an investigational triple-action agonist that targets GIP, GLP-1, and glucagon. In studies it increased calories burned and helped reduce liver fat.
- Clinical trials reported average weight loss of about 15% with semaglutide, 20% to 22% with tirzepatide, and most recently, a staggering 28.3% for retatrutide.
- All three can cause gastrointestinal side effects and some users have reported changes in mood.
- Why People Start Looking: The Reality of Chronic Weight Management
- Which GLP-1 Drug Is Best for Weight Loss? Understanding the Evolution
- Side-by-Side Comparison: Semaglutide vs. Tirzepatide vs. Retatrutide
- Tirzepatide vs. Semaglutide vs. Retatrutide: Which May Be Right for You?
- What Are the Side Effects of Weight Loss Peptides? The Anhedonia Question
Why People Start Looking: The Reality of Chronic Weight Management
Most people do not start researching these medications because they want to lose a few quick pounds. They start because they have spent years, sometimes decades, fighting a biological system that is actively working against them.
The medical community no longer views obesity as simply a failure of willpower. It’s recognized as a complex, chronic metabolic disease. When a person loses weight through diet and exercise, the body can respond by slowing metabolism and increasing hunger signals. This survival response can make keeping the weight off much harder.
For millions of people, persistent thoughts about food or “food noise” can make trying to achieve a calorie deficit feel like a full-time job. GLP-1-based medications are designed to change how the brain and gut communicate. They can turn down appetite signals and help some patients eat less without feeling constantly deprived.
Which GLP-1 Drug Is Best for Weight Loss? Understanding the Evolution
As patient awareness grows, people are no longer just searching brand names. They’re looking for the best GLP-1 medication for their needs. The answer depends entirely on how the peptide works (mechanism of action). The field has moved from single-hormone targeting to dual-hormone targeting and now to investigational triple-hormone targeting.
Semaglutide: The Single-Action Breakthrough
Semaglutide is the active ingredient in Ozempic (approved for type 2 diabetes) and Wegovy (approved for chronic weight management). It belongs to a class called GLP-1 receptor agonists.
GLP-1 (glucagon-like peptide-1), is a hormone the intestines naturally release after eating. It signals the pancreas to release insulin, slows how quickly the stomach empties, and travels to the brain to support feelings of fullness.1
In the landmark STEP clinical trials, adults taking the highest dose of Wegovy lost an average of about 15% of their body weight over 68 weeks.4 In the SELECT trial, semaglutide reduced major cardiovascular events among adults with cardiovascular disease and overweight or obesity but without diabetes.7 In 2024, the FDA did approve Wegovy to reduce the risk of cardiovascular evens in adults with cardiovascular disease and obesity.
Tirzepatide: The Dual-Action Standard
Tirzepatide is the active ingredient in Mounjaro (approved for type 2 diabetes), and Zepbound (approved for chronic weight management). While often grouped with GLP-1 medications, it’s actually a dual agonist. It mimics GLP-1 just like semaglutide does, but it also mimics a second gut hormone called GIP (glucose-dependent insulinotropic polypeptide).2
GIP works with GLP-1 to help regulate blood sugar and also has distinct effects on metabolism and fat storage. By targeting both receptors, tirzepatide can reduce appetite while improving insulin sensitivity. In the SURMOUNT clinical trials, adults taking the highest dose lost an average of 20.9% of their body weight over 72 weeks.5 In a direct 2025 comparison, mean weight loss was 20.2% with tirzepatide and 13.7% with semaglutide.8
What Comes After Ozempic and Mounjaro? Enter Retatrutide
The next frontier in metabolic medicine is retatrutide, an investigational medication, developed by Eli Lilly. The Phase 3 clinical trials (the TRIUMPH program) have concluded but are not yet fully peer-reviewed. Retatrutide is not FDA-approved for any use.
Retatrutide is a “triple agonist.” It targets GLP-1 and GIP (like tirzepatide), but adds a third hormone receptor: glucagon.9 Glucagon is traditionally known for raising blood sugar, but in this three-hormone combination, it may also increase the number of calories the body burns and help reduce liver fat.3
The Phase 3 data involving retatrutide was staggering. In the TRIUMPH-1 trial, participants on the highest dose (12 mg) lost an average of 28.3% of their body weight over 80 weeks. Over 45% of participants achieved at least a 30% weight reduction, a level of weight loss previously only seen with bariatric surgery.10
Did You Know?
Both semaglutide and tirzepatide were originally developed to treat type 2 diabetes. It was only during the diabetes clinical trials that researchers noticed patients were consistently losing significant amounts of weight, prompting entirely new trials focused specifically on obesity.
Side-by-Side Comparison: Semaglutide vs. Tirzepatide vs. Retatrutide
| Profile | Semaglutide (Ozempic, Wegovy) | Tirzepatide (Mounjaro, Zepbound) | Retatrutide (Investigational) |
| Mechanism of Action | Single GLP-1 receptor agonist | Dual GIP and GLP-1 receptor agonist | Triple GIP, GLP-1, and glucagon receptor agonist |
| FDA Approval Status | Approved for type 2 diabetes as Ozempic and for chronic weight management as Wegovy | Approved for type 2 diabetes as Mounjaro and for chronic weight management as Zepbound | Not FDA-approved. Phase 3 TRIUMPH-1 completed.10 |
| How It Is Taken | Once-weekly injection; oral semaglutide products are also available for certain indications | Once-weekly injection | Once-weekly injection in clinical trials only |
| Dose Range Discussed in the Source Article | Injection: 0.25 mg weekly up to 2.4 mg weekly; oral doses vary by product and indication | 2.5 mg weekly up to 15 mg weekly | Participants started at 2 mg and increased to their target dose.10 |
| Average Weight Loss in Cited Trials | About 15% at the highest dose studied.4 | About 20% to 22% at the highest doses studied.5 | 28.3% average weight loss at 80 weeks with 12 mg.10 |
| Head-to-Head Evidence | In SURMOUNT-5, mean weight loss was 13.7% with semaglutide.8 | In SURMOUNT-5, mean weight loss was 20.2% with tirzepatide.8 | No head-to-head comparison with semaglutide or tirzepatide has been reported |
| Distinct Evidence Point | Semaglutide reduced major cardiovascular events in the SELECT trial among adults with cardiovascular disease and overweight or obesity but without diabetes.7 | Produced greater mean weight loss than semaglutide in the cited head-to-head trial.8 | Researchers estimated that 45.3% of participants receiving 12 mg lost at least 30% of their body weight at 80 weeks.10 |
| Common Physical Side Effects | Nausea, diarrhea, vomiting, constipation, stomach pain, and fatigue | Nausea, diarrhea, vomiting, constipation, and upset stomach | Nausea, diarrhea, constipation, and vomiting were common. In the 12 mg group, 11.3% discontinued treatment because of adverse events.10 |
Tirzepatide vs. Semaglutide vs. Retatrutide: Which May Be Right for You?
The choice between these medications depends on clinical goals, medical history, side-effect tolerance, availability, and the judgment of a licensed healthcare provider.
If you value the longest track record, semaglutide has years of real-world use and showed reduced major cardiovascular events in the SELECT trial among adults with cardiovascular disease who were overweight or obese but did not have diabetes.7
If your provider is weighing the strongest head-to-head weight-loss data available, tirzepatide produced greater mean weight loss than semaglutide in SURMOUNT-5.8 That does not mean it’s automatically the right medication for every patient.
If you are watching what may come next, retatrutide represents a new triple-agonist approach. However, it is still investigational, its full safety profile is still being established, and it is not available as an FDA-approved treatment.
What Are the Side Effects of Weight Loss Peptides? The Anhedonia Question
Because these medications work through overlapping pathways, they share many of the same physical side effects. The most common are gastrointestinal: nausea, diarrhea, vomiting, and constipation. These effects are often strongest when treatment begins or the dose increases.
Approved GLP-1 medications carry boxed warnings about thyroid C-cell tumors based on rodent studies. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should discuss these warnings with a licensed healthcare provider.
Another possible side effect researchers are paying close attention to is how they affect mood. These drugs act on the brain’s reward centers to reduce “food noise,” Because they dampen the dopamine response to food, there is growing concern that they may dampen the reward response to other pleasures as well.
The cited peer-reviewed retatrutide Phase 2 trial reported gastrointestinal events and temporary dose-dependent increases in heart rate; it did not establish anhedonia as a confirmed drug-related adverse event.6 Reports of mood changes still deserve careful clinical evaluation rather than an assumption that the medication caused them.
Anyone experiencing worsening depression, anxiety, loss of interest in daily life, or other concerning mood changes while using one of these medications should contact a healthcare provider promptly. Mood symptoms can have many causes. These are powerful metabolic treatments that require medical supervision and a long-term plan for weight management.
The Verdict
These three medications represent the most significant shift in weight management in decades. Semaglutide was the breakthrough, proving that targeting the GLP-1 hormone could produce significant, sustained weight loss. Tirzepatide built on that by adding a second hormone target, GIP, which consistently translates to greater weight loss in head-to-head trials. Now, retatrutide (investigational, not FDA-approved) has added a third hormone target, glucagon, showing unprecedented average body weight loss. The right choice often comes down to individual goals, tolerance for side effects, and FDA availability.
Talk With a Licensed Healthcare Provider
A qualified provider can review your medical history, explain which FDA-approved options may fit your needs, and help you understand the limits of investigational treatments. Explore our verified providers.
Semaglutide targets a single hormone receptor (GLP-1) to slow digestion and signal fullness to the brain. Tirzepatide targets two hormone receptors (GLP-1 and GIP), which produces a stronger combined effect on appetite and metabolism. In a 2025 head-to-head clinical trial, tirzepatide produced greater average weight loss than semaglutide over the same time period.
Retatrutide is not FDA-approved and is not available outside of clinical trials. It is currently in Phase 3 trials (the TRIUMPH program) developed by Eli Lilly. If approved, retatrutide would become the first triple-agonist weight loss medication available by prescription.
Among currently FDA-approved options, tirzepatide (Zepbound) has produced the greatest average weight loss in clinical trials, approximately 20 to 22 percent of body weight at the highest doses. Retatrutide has shown even greater results in Phase 3 data (approximately 28 percent), but it is not yet approved. Individual results vary and depend on dose, duration, lifestyle factors, and individual response.
Anhedonia is a condition characterized by an inability to feel pleasure or motivation. Because GLP-1 medications work partly by reducing the brain’s dopamine response to food, there is concern that they may also reduce the reward response to other activities. Retatrutide’s triple-receptor action is more potent than earlier compounds, and emerging reports from trials have noted emotional flattening, anxiety, and anhedonia in some participants. Anyone experiencing these symptoms should speak with their healthcare provider immediately.
Switching between these medications is a clinical decision that should be made with a licensed healthcare provider. Some patients who have plateaued on semaglutide have been transitioned to tirzepatide under medical supervision. The transition protocol, timing, and dosing should be managed by a qualified provider based on your individual health history and goals.
Scientific References
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism. 2021;46:101102.
- Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovascular Diabetology. 2022;21(1):169.
- Coskun T, Urva SR, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.e9.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021;384(11):989-1002.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity – a Phase 2 trial. New England Journal of Medicine. 2023;389(6):514-526.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389(24):2221-2232.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine. 2025;393(1):26-36.
- Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2026;28(1):83-93.
- Jastreboff AM. The first phase 3 obesity study of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with obesity (TRIUMPH-1). Presented at: American Diabetes Association 86th Scientific Sessions; June 6, 2026; New Orleans, LA.
Legal & Medical Disclaimer
The information provided on this page by PeptideMatch.io is intended solely for educational and informational purposes. It does not constitute, and should not be interpreted as, professional medical advice, diagnosis, or treatment. Always consult a licensed physician or qualified healthcare provider before beginning any therapy or making changes to an existing treatment plan. Retatrutide is investigational and is not FDA-approved. PeptideMatch.io does not prescribe, dispense, or endorse any specific therapeutic protocol. Individual results may vary, and no outcomes are guaranteed. Medication costs and availability can change.
©2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io.
Related Posts
Understanding the difference between PT-141 (bremelanotide) and sildenafil for treating sexual
Energy decline, brain fog, slow recovery—NAD+ is at the center of all of it. Here are options to restore
The science behind using specific signaling molecules to help restore balance, stamina, and wellness during
Ready to take the next step?
Find a verified peptide therapy provider or list your practice and connect with patients actively seeking trusted care.